Drug Profile
Research programme: receptor tyrosine kinase targeting monoclonal antibodies - Celldex Therapeutics Inc
Alternative Names: ALK-ADC; Anti-MET antibodies - Celldex; Anti-MET humanised monoclonal antibody - Celldex; KTN-0073; KTN-0125; KTN0125-TEILatest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator University of Toronto; Yale University School of Medicine
- Developer Celldex Therapeutics Inc
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Proto-oncogene protein c-met inhibitors; Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Neuroblastoma
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 09 Nov 2020 Receptor tyrosine kinase targeting monoclonal antibodies is still in preclinical trials for Cancer in USA
- 09 Nov 2020 Pharmacodynamics data from a preclinical trial in Cancer presented at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020)